Getting Closer…

Saturday 17th Jan

• Blood Tests: The FDA has approved blood tests to detect early-stage Alzheimer's by identifying amyloid plaques, providing a less invasive, cheaper alternative to PET scans or lumbar punctures.
• Key Biomarkers: Measurements of a specific form of tau protein, p-tau217, have significantly improved the accuracy of these blood tests in clinical settings.
• Early Prediction: Research suggests that signs of cognitive impairment can be detected 11–15 years before symptoms appear, with certain tau proteins appearing up to 34 years before onset. 

• Disease Reversal (Animal Models): A 2025 study showed that reversing brain energy imbalance could reverse Alzheimer's pathology in mice, offering hope for future treatments that go beyond just removing plaques.
• New Drug Trials: The drug NNI-362 is being tested in trials for its ability to generate new neurons and reduce Alzheimer's biomarkers in the brain.
• Immunotherapy: Research into modifying the TREM1 level in macrophages may help control brain inflammation, as elevated levels of this protein are associated with higher risk.
• Anti-Amyloid Drugs: New, easier-to-administer (subcutaneous injection) versions of amyloid-clearing drugs like Leqembi (lecanemab) are in use for early-stage patients. 

• Modifiable Risk: Approximately 45% of dementia risk is linked to modifiable factors, including midlife hypertension, obesity, smoking, physical inactivity, and untreated hearing loss.
• Vascular Connection: A gene named FMNL2 has been identified as a link between cerebrovascular disease and Alzheimer's, suggesting that vascular health directly impacts the brain's ability to clear toxic proteins.
• Lifestyle Factors: High blood sugar after meals has been strongly linked to increased risk, highlighting the importance of diet management. 

• Alzheimer's and COVID-19: Research has detected increased levels of the protein tau in the blood of individuals with long-COVID neurocognitive symptoms, suggesting a potential link to future neurodegenerative risks.
• "Garbage" Clearance: Researchers are investigating how boosting specific proteins, such as Sox9, can help brain cells clear out toxic plaques.
• APOE Genetic Driver: Studies indicate that the APOE ε3 and ε4 gene variants are linked to over 70% of Alzheimer's cases, reinforcing their importance in future targeted treatments. 

---